| 12415809 |
Pyrrolotriazine compounds as tam inhibitors |
Yun-Long Li, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn +4 more |
2025-09-16 |
|
| 12378243 |
Quinoline compounds as inhibitors of KRAS |
Qinda Ye, Matthew S. McCammant, Rocco Policarpo, Artem Shvartsbart, Wenyu Zhu +13 more |
2025-08-05 |
|
| 12331063 |
Hetero-bicyclic inhibitors of KRAS |
Alexander Sokolsky, Chang Min, Wenqing Yao |
2025-06-17 |
|
| 12077539 |
Imidazole and triazole KRAS inhibitors |
Chao Qi, Wenqing Yao |
2024-09-03 |
$81,309,000 |
| 12060433 |
CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy |
Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane +9 more |
2024-08-13 |
$73,572,000 |
| 12030884 |
Pyrazoloquinoline KRAS inhibitors |
Wenyu Zhu, Wenqing Yao |
2024-07-09 |
$15,981,000 |
| 12030883 |
Hetero-tricyclic compounds as inhibitors of KRAS |
Peter Carlsen, Ken Mukai, Haolin Yin, Wenqing Yao, Wenyu Zhu |
2024-07-09 |
$15,981,000 |
| 11999752 |
Vinyl imidazole compounds as inhibitors of KRAS |
Peter Carlsen, Alexander Sokolsky, Pei Gan, Rocco Policarpo, Wenqing Yao |
2024-06-04 |
$26,035,000 |
| 11999740 |
Fused pyrazine derivatives as A2A / A2B inhibitors |
Peter Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi +3 more |
2024-06-04 |
$26,035,000 |
| 11976073 |
Bicyclic amines as CDK2 inhibitors |
Joshua Hummel, David M. Burns, Ding-Quan Qian |
2024-05-07 |
$69,067,000 |
| 11939328 |
Quinoline compounds as inhibitors of KRAS |
Qinda Ye, Matthew S. McCammant, Artem Shvartsbart, Wenyu Zhu, Bin Hu +3 more |
2024-03-26 |
$38,229,000 |
| 11884665 |
Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
Taisheng Huang |
2024-01-30 |
$78,082,000 |
| 11873304 |
Fused pyrimidine derivatives as A2A/A2B inhibitors |
Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu +1 more |
2024-01-16 |
$40,689,000 |
| 11767320 |
Bicyclic dione compounds as inhibitors of KRAS |
Taisheng Huang, Wenqing Yao |
2023-09-26 |
$37,874,000 |
| 11739102 |
Fused pyrimidine compounds as KRAS inhibitors |
Gia Hoang, Wenqing Yao |
2023-08-29 |
$39,208,000 |
| 11673894 |
Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu +5 more |
2023-06-13 |
$39,837,000 |
| 11591338 |
Pyrrolotriazine compounds as TAM inhibitors |
Yun-Long Li, Chunhong He |
2023-02-28 |
$17,306,000 |
| 11530218 |
Spiro compounds as inhibitors of KRAS |
Le Zhao, Wenyu Zhu, Haolin Yin, Liangxing Wu, Wenqing Yao |
2022-12-20 |
$109,117,000 |
| 11390624 |
Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
Taisheng Huang |
2022-07-19 |
$117,304,000 |
| 11247992 |
Cyclopropylamines as LSD1 inhibitors |
Liangxing Wu, Joel R. Courter, Chunhong He, Wenqing Yao, Fenglei Zhang |
2022-02-15 |
$101,732,000 |
| 11220510 |
Pyrrole tricyclic compounds as A2A / A2B inhibitors |
Peter Carlsen, Chunhong He, Taisheng Huang |
2022-01-11 |
$54,624,000 |
| 11168089 |
Fused pyrimidine derivatives as A2A / A2B inhibitors |
Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu +1 more |
2021-11-09 |
$99,617,000 |
| 11161850 |
Fused pyrazine derivatives as A2A / A2B inhibitors |
Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu |
2021-11-02 |
$33,545,000 |
| 11136326 |
Pyrrolopyrimidine derivatives as TAM inhibitors |
Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He +3 more |
2021-10-05 |
$99,349,000 |
| 10968221 |
Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
Liangxing Wu, Wenqing Yao, Colin Zhang |
2021-04-06 |
$73,776,000 |